TY - JOUR
T1 - Association of Penicillin or Cephalosporin Allergy Documentation and Antibiotic Use in Hospitalized Patients with Pneumonia
AU - Mancini, Christian M.
AU - Wimmer, Megan
AU - Schulz, Lucas T.
AU - Zhang, Yuqing
AU - Fu, Xiaoqing
AU - Postelnick, Michael
AU - Bhowmick, Tanaya
AU - Lee, Francesca
AU - Blumenthal, Kimberly G.
N1 - Funding Information:
K. G. Blumenthal receives career development support from the National Institutes of Health (NIH) K01AI125631, the American Academy of Allergy Asthma and Immunology (AAAAI) Foundation, and the Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, AAAAI Foundation, nor the MGH. No funding for this study was received from Vizient, Inc.
Funding Information:
K. G. Blumenthal receives career development support from the National Institutes of Health (NIH) K01AI125631 , the American Academy of Allergy Asthma and Immunology (AAAAI) Foundation , and the Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, AAAAI Foundation, nor the MGH. No funding for this study was received from Vizient, Inc.
Publisher Copyright:
© 2021 American Academy of Allergy, Asthma & Immunology
PY - 2021/8
Y1 - 2021/8
N2 - Background: Treatment guidelines for pneumonia recommend beta-lactam antibiotic-based therapy. Although reported penicillin allergy is common, more than 90% of patients with reported penicillin allergy are not allergic. Objective: We evaluated the association of a documented penicillin and/or cephalosporin (P/C) allergy to antibiotic use for the treatment of inpatient pneumonia. Methods: This was a national cross-sectional study conducted among Vizient, Inc., network hospitals that voluntarily contributed data. Among hospitalized patients with pneumonia, we examined the relation of a documented P/C allergy in the electronic health record to prevalence of first-line beta-lactam antibiotic administration and alternative antibiotics using multivariable log-binomial regression with generalized estimating equations. Results: Of 2,276 inpatients receiving antibiotics for pneumonia at 95 U.S. hospitals, 450 (20%) had a documented P/C allergy. Compared with pneumonia patients without a documented P/C allergy, patients with a documented P/C allergy had reduced prevalence of first-line beta-lactam antibiotic use (adjusted prevalence ratio [aPR] 0.79; 95% confidence interval [95% CI] 0.69-0.89]). Patients with high-risk P/C reactions (n = 91) had even lower prevalence of first-line beta-lactam antibiotic use (aPR 0.47; 95% CI 0.35-0.64). Alternative antibiotics associated with a higher use in pneumonia patients with a documented P/C allergy included carbapenems (aPR 1.61; 95% CI 1.22-2.13) and fluoroquinolones (aPR 1.52; 95% CI 1.21-1.91). Conclusions: Inpatients with documented P/C allergy and pneumonia were less likely to receive recommended beta-lactams and more likely to receive carbapenems and fluoroquinolones. Inpatient allergy assessment may improve optimal antibiotic therapy for the 20% of inpatients with pneumonia and a documented P/C allergy.
AB - Background: Treatment guidelines for pneumonia recommend beta-lactam antibiotic-based therapy. Although reported penicillin allergy is common, more than 90% of patients with reported penicillin allergy are not allergic. Objective: We evaluated the association of a documented penicillin and/or cephalosporin (P/C) allergy to antibiotic use for the treatment of inpatient pneumonia. Methods: This was a national cross-sectional study conducted among Vizient, Inc., network hospitals that voluntarily contributed data. Among hospitalized patients with pneumonia, we examined the relation of a documented P/C allergy in the electronic health record to prevalence of first-line beta-lactam antibiotic administration and alternative antibiotics using multivariable log-binomial regression with generalized estimating equations. Results: Of 2,276 inpatients receiving antibiotics for pneumonia at 95 U.S. hospitals, 450 (20%) had a documented P/C allergy. Compared with pneumonia patients without a documented P/C allergy, patients with a documented P/C allergy had reduced prevalence of first-line beta-lactam antibiotic use (adjusted prevalence ratio [aPR] 0.79; 95% confidence interval [95% CI] 0.69-0.89]). Patients with high-risk P/C reactions (n = 91) had even lower prevalence of first-line beta-lactam antibiotic use (aPR 0.47; 95% CI 0.35-0.64). Alternative antibiotics associated with a higher use in pneumonia patients with a documented P/C allergy included carbapenems (aPR 1.61; 95% CI 1.22-2.13) and fluoroquinolones (aPR 1.52; 95% CI 1.21-1.91). Conclusions: Inpatients with documented P/C allergy and pneumonia were less likely to receive recommended beta-lactams and more likely to receive carbapenems and fluoroquinolones. Inpatient allergy assessment may improve optimal antibiotic therapy for the 20% of inpatients with pneumonia and a documented P/C allergy.
KW - Allergy
KW - EHR data
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85107938997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107938997&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.04.071
DO - 10.1016/j.jaip.2021.04.071
M3 - Article
C2 - 34029776
AN - SCOPUS:85107938997
SN - 2213-2198
VL - 9
SP - 3060-3068.e1
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -